De Souza, Daniel C.
Hebert, Nicolas
Esrick, Erica B.
Ciuculescu, M. Felicia
Archer, Natasha M.
Armant, Myriam http://orcid.org/0000-0002-5205-3003
Audureau, Étienne
Brendel, Christian http://orcid.org/0000-0003-4081-4351
Di Caprio, Giuseppe http://orcid.org/0000-0001-5564-8064
Galactéros, Frédéric
Liu, Donghui
McCabe, Amanda
Morris, Emily
Schonbrun, Ethan
Williams, Dillon
Wood, David K. http://orcid.org/0000-0001-5225-2144
Williams, David A.
Bartolucci, Pablo
Higgins, John M. http://orcid.org/0000-0002-9182-0076
Article History
Received: 19 December 2022
Accepted: 14 August 2023
First Online: 20 September 2023
Competing interests
: The following authors declare the following relationships which may be considered as potential competing interests: E.B.E.: bluebird bio: Consultancy. D.A.W.: Emerging Therapy Solutions: Chief Scientific Chair (consulting position, ended in 2021); Skyline Therapeutics (formerly Geneception): Scientific Advisory Board; BioMarin: Insertion Site Advisory Board; Novartis: Committee, Novartis ETB115E2201 (eltrombopag in aplastic anemia). Advisory fees donated to NAPAAC; Alerion Biosciences: Co-founder (now licensed to Avro Bio, potential for future milestones/royalties); Beam Therapeutics: Scientific Advisory Board; Orchard Therapeutics: Scientific Advisory Board (position ended 05/20/2021) and co-founder. bluebird bio provided GMP vector for a clinical trial (sickle cell disease) and Insertion Site Analysis Advisory Board. P.B.: Consultant for ADDMEDICA, Novartis, ROCHE, GBT, bluebird bio, EMMAUS, HEMANEXT, AGIOS, VERTEX; Lecture fees for Novartis, ADDMEDICA, AGIOS, JAZZPHARMA, VERTEX; Steering committee for Novartis and ADDMEDICA; Research support from ADDMEDICA, foundation Fabre, Novartis, bluebird bio, EMMAUS, GBT; Cofounder of INNOVHEM. The authors not listed here declare no competing interests.